Inhibitor Report for: Talinolol Unselective antagonist of the beta adrenergic receptors (betaAR). Inhibitor of soluble epoxide hydrolase IC50 2.8+/-0.2 muM General
Type Urea derivative , Not A/B H target , Adrenergic-Receptor-ligand Chemical_Nomenclature 1-[4-[3-(~{tert}-butylamino)-2-hydroxypropoxy]phenyl]-3-cyclohexylurea Canonical SMILES CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O InChI InChI=1S/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25) InChIKey MXFWWQICDIZSOA-UHFFFAOYSA-N Other name(s) Cordanum ; Racemic talinolol
________________________________________________________________________________________________
Target
Families | Talinolol ligand of proteins in family: Epoxide_hydrolase Stucture | 1 structure : 6HGV : Human soluble epoxide hydrolase in complex with talinolol Protein | human-EPHX2
References:
Search PubMed for references concerning:
Talinolol
Title: Computer-Aided Selective Optimization of Side Activities of TalinololHiesinger K , Kramer JS , Achenbach J , Moser D , Weber J , Wittmann SK , Morisseau C , Angioni C , Geisslinger G and Proschak E <7 more author(s)> Hiesinger K , Kramer JS , Achenbach J , Moser D , Weber J , Wittmann SK , Morisseau C , Angioni C , Geisslinger G , Kahnt AS , Kaiser A , Proschak A , Steinhilber D , Pogoryelov D , Wagner K , Hammock BD , Proschak E (- 7) Ref: ACS Med Chem Lett, 10 :899, 2019 : PubMed Abstract ESTHER: Hiesinger_2019_ACS.Med.Chem.Lett_10_899 PubMedSearch: Hiesinger 2019 ACS.Med.Chem.Lett 10 899 PubMedID: 31223445 Gene_locus related to this paper: human-EPHX2 Inhibitor(s) related to this paper: G3W ,
Talinolol ,
Morpholino-Talinolol Abstract
Selective optimization of side activities is a valuable source of novel lead structures in drug discovery. In this study, a computer-aided approach was used to deorphanize the pleiotropic cholesterol-lowering effects of the beta-blocker talinolol, which result from the inhibition of the enzyme soluble epoxide hydrolase (sEH). X-ray structure analysis of the sEH in complex with talinolol enables a straightforward optimization of inhibitory potency. The resulting lead structure exhibited in vivo activity in a rat model of diabetic neuropatic pain.
